ALK and non-small cell lung carcinoma: Then, the KEYNOTE-042 study suggested that pembrolizumab monotherapy was an efficacious first-line therapy to patients with locally advanced or metastatic NSCLC without EGFR or ALK alterations or high PD-L1 TPS who may not tolerate chemotherapy (20).